Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 392

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 8
Chunk 392
---
 investments:  Money market funds$184,139 $— $— $184,139 Corporate debt securities67,392 66 (6)67,452 U.S. government bonds25,919 35 (1)25,953 Commercial paper4,371 — — 4,371 Total cash equivalents and investments$281,821 $101 $(7)$281,915 Classified as:  Cash equivalents $188,373 Short-term investments76,430 Long-term investments17,112 Total cash equivalents and investments $281,915  December 31, 2024 AmortizedCostUnrealizedGainUnrealizedLoss EstimatedFairValueCash equivalents:Money market funds$202,965 $— $— $202,965 U.S. treasury bills$2,957 $7 $— $2,964 Corporate debt securities$37,942 $50 $(14)$37,978 U.S. government bonds$26,819 $90 $(5)$26,904 Agency bonds$2,490 $2 $— $2,492 Total cash equivalents and investments$273,173 $149 $(19)$273,303 Classified as:Cash equivalents$202,965 Short-term investments57,812 Long-term investments12,526 Total cash equivalents and investments$273,303 As of June 30, 2025, the remaining contractual maturities of available-for-sale debt securities were as follows (in thousands):Estimated Fair ValueDue within one year$80,664 One to two years17,112 Total$97,776 

During the three and six months ended June 30, 2025 and 2024, there have been no significant realized gains or losses on available-for-sale investments, no investments have been in a continuous unrealized loss position for more than 12 months, and the Company did not recognize any material unrealized gains or losses on these securities. 

12

5. Balance Sheet Components

InventoryInventory consists of the following (in thousands): June 30,2025December 31,2024Raw materials$2,923 $3,030 Work in progress16,310 16,089 Finished goods3,708 3,284 Total inventory$22,941 $22,403 Intangible